Navigation Links
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Date:6/13/2008

- Phase III monotherapy study shows ACTEMRA is first and only biologic to demonstrate statistical superiority over methotrexate after 24 weeks of

treatment -

PARIS, June 13 /PRNewswire/ -- Patients who suffer the chronic and debilitating effects of rheumatoid arthritis (RA) -- despite treatment with current therapies -- achieved significant improvements in signs and symptoms when treated with Roche's ACTEMRA(R) (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone, according to two international Phase III studies presented by researchers at the European Congress of Rheumatology (ECR) held by the European League Against Rheumatism (EULAR) in Paris.

Data from two new Phase III studies -- RADIATE and AMBITION trials -- will be highlighted as oral presentations at the congress, along with 21 additional abstracts involving ACTEMRA, a novel interleukin-6 (IL-6) receptor inhibitor being studied for the treatment of moderate to severe RA. Importantly, findings from the RADIATE study were also published online this week in the Annals of the Rheumatic Diseases.

In the RADIATE study, which evaluated difficult-to-treat patients who failed to respond to prior anti-TNF therapies, 50 percent of ACTEMRA-treated patients achieved a 20 percent (ACR20(1)) reduction in signs and symptoms. The AMBITION study showed that significantly more patients receiving ACTEMRA achieved a 20 percent improvement in their signs and symptoms [ACR20: 70%]. No previous biologic therapy has demonstrated statistically significant superiority compared to methotrexate in this important clinical parameter at week 24. In addition, nearly one-third of all ACTEMRA patients from both studies reached disease remission (as defined by DAS28 <2.6(2)).

"We are very encouraged by the results of the AMBITION study that shows for the first time that treatment with a single biologic agent is superior to methotrexate at s
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
5. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
10. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
11. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Mich. , Aug. 22, 2014  Dr. ... Who with the Diamond Lifetime Achievement Award in the ... as CEO of Cardiovascular Clinical Associates. Dr. ... in managing all major aspects of the business; overseeing ... well as primary coronary intervention. In addition, he is ...
(Date:8/22/2014)... Zacks Equity Research highlights Epizyme (Nasdaq: EPZM - Free ... PNRA - Free Report ) as the Bear of the ... (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: SNY ... Report ). Here is a synopsis of all five ... The biotech bull market is far from over due ...
(Date:8/22/2014)... ITHACA, N.Y. , Aug. 22, 2014 /PRNewswire/ ... computed tomography (CT) imaging facility, is using the ... 4D and even 5D imaging to researchers and ... just launched, asks "What would YOU do if ... the possibility to researchers and explorers everywhere, from ...
Breaking Medicine Technology:Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2
... Eli Lilly and Company (NYSE: LLY ) will ... on Wednesday, April 25, 2012.  Lilly will also conduct a ... media to further detail the company,s financial performance. ... to 10:00 a.m. EDT.  Investors, media and the general public ...
... Inc. , a biopharmaceutical company focused on the discovery, ... is in the human nervous system, today announced that ... the treatment of cough has cleared the 30 day ... (FDA).  The Company plans to immediately characterize the pharmacokinetics ...
Cached Medicine Technology:Cerecor Announces Clearance of IND for FP01 2
(Date:8/22/2014)... The improved access to antiretroviral drugs ... developing world, has led to the decline in the ... due to AIDS globally. However, despite the fact that ... patients becoming affected by the virus is on the ... all related organisations and stakeholders, by 2015, significant investments ...
(Date:8/22/2014)... A national leader in home delivery of ... room to grow. , Headquarters for the provider of sterile-use ... building at 8516 N.W. Expressway in Oklahoma City. , ... Oklahoma’s best places to work by OKCBiz magazine – demanded ... 120 in the past two years, and staff count grew ...
(Date:8/22/2014)... 2014 (HealthDay News) -- People who use reduced-nicotine cigarettes ... levels of nicotine, according to a new study. ... other smokers, the researchers say. The month-long study ... smoked regular cigarettes with nicotine emission levels of 1.2 ... switched to reduced-nicotine cigarettes for the next three weeks. ...
(Date:8/22/2014)... years, several breakthrough treatments have become available for ... benefit from these treatments can be pre-identified by ... For example, patients whose lung cancer is driven ... benefit from the drug crizotinib, which targets this ... to replicate this success by matching different drugs ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Ticket Down ... tickets in Kalamazoo, New Orleans, Albuquerque and Rapid City. ... the “Long Island Medium,” Theresa Caputo, allows just that. Caputo ... She is part of a close knit family who began ... with a spiritual healer, realized she had a chance to ...
Breaking Medicine News(10 mins):Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:Fast-growing 180 Medical Moves Into New 60,000-square-foot Office in Oklahoma City 2Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2
... likely than Caucasians and men to undergo bone marrow ... the conclusion of a new analysis published early online ... American Cancer Society. The study,s results indicate that additional ... access to bone marrow transplantation and also that the ...
... ... ... Readers will be struck by the illuminative work of a mature poet as author Brad ... its name, this reflective anthology reveals the profound emotions and sentiments of a man who, ...
... “The reviews were amazing. ... BMEGateway to give a symposium to our loyal client base that was enjoyable and memorable on ... like this.” , ... (PRWEB) May 23, 2010 -- BMEGateway, the national leader in independent medical evaluation, peer/medical review ...
... people to protect their ears when going to firework displays, ... most common sounds of summer can expose listeners to permanent ... was sounded by David Coffin, director of Ball State University,s ... come in the form of the pop of fireworks, the ...
... ... celiac disease , ... (PRWEB) May 22, 2010 -- LoveToKnow, Inc. has launched a new Web site channel that ... addition, as part of a campaign to help people with these issues, the company said ...
... ... residential solar energy systems in Bensalem, Pennsylvania. The systems are the first operating systems ... the region. The projects were primarily funded through the Pennsylvania Sunshine Fund and Federal ... West Chester, ...
Cached Medicine News:Health News:African-Americans and women are less likely to undergo bone marrow transplantation 2Health News:The Heart of the Prisoner Revealed 2Health News:BMEGateway's 20th Anniversary Insurance Symposium considered a &#8220;Tremendous&#8221; Success 2Health News:Summer Sounds Can Lead to Hearing Loss 2Health News:LoveToKnow.com Launches Gluten Free Channel and Will Donate to National Foundation for Celiac Awareness 2Health News:LoveToKnow.com Launches Gluten Free Channel and Will Donate to National Foundation for Celiac Awareness 3Health News:Pennsylvania's Newest Power Companies Right in Your Neighbor's Back Yard 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: